Award Number: W81XWH-06-1-0630 TITLE: A Targeted Mulifunctional Platform for Imaging and Treatment of Breast Cancer and Its Metastases Based on Adenoviral Vectors and Magnetic Nanoparticles
暂无分享,去创建一个
Mark Ellisman | S. Mirov | G. Perkins | V. Zharov | A. Perez | H. Green | V. Saini | M. Everts | M. R. Enervold | A. Koploy
[1] R. Desmond,et al. A three-dimensional assay for measurement of viral-induced oncolysis , 2007, Cancer Gene Therapy.
[2] S. Russell,et al. Engineering oncolytic measles virus to circumvent the intracellular innate immune response. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[3] Shuming Nie,et al. Cell-penetrating quantum dots based on multivalent and endosome-disrupting surface coatings. , 2007, Journal of the American Chemical Society.
[4] A. Rivera,et al. Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer , 2007, International journal of cancer.
[5] Shuming Nie,et al. Quantum dots for in vivo molecular and cellular imaging. , 2007, Methods in molecular biology.
[6] E. Genden,et al. Interleukin‐12 Expression Enhances Vesicular Stomatitis Virus Oncolytic Therapy in Murine Squamous Cell Carcinoma , 2007, The Laryngoscope.
[7] S. Indraccolo,et al. Angiogenesis meets immunology: cytokine gene therapy of cancer. , 2007, Molecular aspects of medicine.
[8] S. Indraccolo,et al. Anti-angiogenic gene therapy of cancer: current status and future prospects. , 2007, Molecular aspects of medicine.
[9] J. Mathis,et al. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma , 2007, Breast Cancer Research and Treatment.
[10] A. Oberg,et al. The Use of a Tropism-Modified Measles Virus in Folate Receptor–Targeted Virotherapy of Ovarian Cancer , 2006, Clinical Cancer Research.
[11] S. Rosenberg,et al. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.
[12] V. Zharov,et al. Combination of viral biology and nanotechnology: new applications in nanomedicine. , 2006, Nanomedicine : nanotechnology, biology, and medicine.
[13] P. Nielsen,et al. Enhanced delivery of cell-penetrating peptide–peptide nucleic acid conjugates by endosomal disruption , 2006, Nature Protocols.
[14] M. Barry,et al. Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. , 2006, Virology.
[15] O. Danos,et al. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice , 2006, Gene Therapy.
[16] T. Park,et al. Folate immobilized and PEGylated adenovirus for retargeting to tumor cells. , 2006, Bioconjugate chemistry.
[17] D. Grimm,et al. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. , 2006, Cardiovascular research.
[18] C. Contag,et al. Synergistic Antitumor Effects of Immune Cell-Viral Biotherapy , 2006, Science.
[19] Vladimir P Zharov,et al. Covalently linked Au nanoparticles to a viral vector: potential for combined photothermal and gene cancer therapy. , 2006, Nano letters.
[20] Sam C. Noureddini,et al. Generation and selection of targeted adenoviruses embodying optimized vector properties. , 2006, Virus research.
[21] D. Curiel,et al. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses , 2006, Molecular Cancer Therapeutics.
[22] D. Dhar,et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. , 2006, Cancer research.
[23] D. Curiel,et al. Transductional targeting of adenovirus vectors for gene therapy , 2006, Cancer Gene Therapy.
[24] Vladimir P Zharov,et al. Self-assembling nanoclusters in living systems: application for integrated photothermal nanodiagnostics and nanotherapy. , 2005, Nanomedicine : nanotechnology, biology, and medicine.
[25] R. Franceschi,et al. Biological Approaches to Bone Regeneration by Gene Therapy , 2005, Journal of dental research.
[26] M. Chillón,et al. Gutless adenovirus: last-generation adenovirus for gene therapy , 2005, Gene Therapy.
[27] L. Old,et al. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. , 2005, Blood.
[28] D. Curiel,et al. Selective induction of tumor-associated antigens in murine pulmonary vasculature using double-targeted adenoviral vectors , 2005, Gene Therapy.
[29] A. Gaggar,et al. Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity , 2005, Journal of Virology.
[30] S. Woo,et al. Treatment of multi‐focal colorectal carcinoma metastatic to the liver of immune‐competent and syngeneic rats by hepatic artery infusion of oncolytic vesicular stomatitis virus , 2005, International journal of cancer.
[31] R. Alemany,et al. Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors , 2005, Cancer Gene Therapy.
[32] A. Beaudet,et al. PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile , 2005, Gene Therapy.
[33] D. Curiel,et al. Identification of Sites in Adenovirus Hexon for Foreign Peptide Incorporation , 2005, Journal of Virology.
[34] C. Kuo,et al. Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy , 2005, Cancer Gene Therapy.
[35] J. Mehta,et al. Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells , 2005, Cancer Gene Therapy.
[36] C. James,et al. Rescue and propagation of fully retargeted oncolytic measles viruses , 2005, Nature Biotechnology.
[37] D. Muruve,et al. The innate immune response to adenovirus vectors. , 2004, Human gene therapy.
[38] R. Samulski,et al. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. , 2004, Annual review of genetics.
[39] M. Andreeff,et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. , 2004, Journal of the National Cancer Institute.
[40] N. Bessis,et al. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms , 2004, Gene therapy.
[41] K. Norman,et al. Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[42] A. Rivera,et al. Transport across a polarized monolayer of Caco-2 cells by transferrin receptor-mediated adenovirus transcytosis. , 2004, Virology.
[43] D. P. O'Neal,et al. Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. , 2004, Cancer letters.
[44] S. Ni,et al. Analysis of Adenovirus Sequestration in the Liver, Transduction of Hepatic Cells, and Innate Toxicity after Injection of Fiber-Modified Vectors , 2004, Journal of Virology.
[45] M. Aprahamian,et al. Carrier cell‐mediated delivery of oncolytic parvoviruses for targeting metastases , 2004, International journal of cancer.
[46] D. Curiel,et al. A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma , 2004, Gene Therapy.
[47] T. Khurana,et al. Therapeutics for Duchenne muscular dystrophy: current approaches and future directions , 2004, Journal of Molecular Medicine.
[48] Florian Kreppel,et al. Long-Term Transgene Expression in Proliferating Cells Mediated by Episomally Maintained High-Capacity Adenovirus Vectors , 2004, Journal of Virology.
[49] J. Shah,et al. Effective Intravenous Therapy of Murine Pulmonary Metastases with an Oncolytic Herpes Virus Expressing Interleukin 12 , 2004, Clinical Cancer Research.
[50] C. Rancourt,et al. Delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for the treatment of ovarian cancer. , 2003, Cytotherapy.
[51] R. Stafford,et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[52] D. Curiel,et al. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. , 2003, Gastroenterology.
[53] D. Curiel,et al. Approaches to Utilize Mesenchymal Progenitor Cells as Cellular Vehicles , 2003, Stem cells.
[54] S. Kitano,et al. Oncolytic viral therapy for human pancreatic cancer cells by reovirus. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[55] D. Kayda,et al. Optimization of the generation and propagation of gutless adenoviral vectors. , 2003, Human gene therapy.
[56] D. Curiel,et al. Construction and Characterization of Adenovirus Serotype 5 Packaged by Serotype 3 Hexon , 2002, Journal of Virology.
[57] R. Vile,et al. The oncolytic virotherapy treatment platform for cancer: Unique biological and biosafety points to consider , 2002, Cancer Gene Therapy.
[58] M. Andreeff,et al. Advances in gene transfer into haematopoietic stem cells by adenoviral vectors , 2002, Expert opinion on biological therapy.
[59] P. Allavena,et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.
[60] M. Raffeld,et al. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.
[61] F. Scappaticci. Mechanisms and future directions for angiogenesis-based cancer therapies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] D. Curiel,et al. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. , 2002, Human gene therapy.
[63] K. Norman,et al. Reovirus oncolysis of human breast cancer. , 2002, Human gene therapy.
[64] C. Ring. Cytolytic viruses as potential anti-cancer agents. , 2002, The Journal of general virology.
[65] D. Curiel,et al. Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. , 2002, Cancer research.
[66] J. He,et al. Retroviral vectors for gene therapy of AIDS and cancer. , 2001, Current opinion in molecular therapeutics.
[67] D. Curiel,et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo , 2001, Nature Biotechnology.
[68] S. Nishikawa,et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. , 2001, Journal of the National Cancer Institute.
[69] A. Flake,et al. Human mesenchymal stem cells persist, demonstrate site-specific multipotential differentiation, and are present in sites of wound healing and tissue regeneration after transplantation into fetal sheep. , 2001, Blood cells, molecules & diseases.
[70] B. Thomson. Viruses and apoptosis , 2001, International journal of experimental pathology.
[71] H. Yoshiji,et al. Intravenous readministration of an adenoviral vector performed long after the initial administration failed to induce re-expression of the original transgene in rats. , 2001, International journal of oncology.
[72] I. Tannock,et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.
[73] Nahum Sonenberg,et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus , 2000, Nature Medicine.
[74] M. Calderwood,et al. Specific oncolytic activity of herpesvirus saimiri in pancreatic cancer cells , 2000, British Journal of Cancer.
[75] E. Wimmer,et al. Intergeneric poliovirus recombinants for the treatment of malignant glioma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[76] J. Grill,et al. Targeting of adenoviral vectors through a bispecific single-chain antibody , 2000, Cancer Gene Therapy.
[77] D. Kirn,et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. , 2000, Cancer research.
[78] James M. Allen,et al. Repeat Transduction in the Mouse Lung by Using Adeno-Associated Virus Vectors with Different Serotypes , 2000, Journal of Virology.
[79] T. McDonnell,et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo , 2000, Oncogene.
[80] K. Propert,et al. Immune responses to adenovirus and adeno-associated virus in humans , 1999, Gene Therapy.
[81] I. Takanami,et al. Tumor-Associated Macrophage Infiltration in Pulmonary Adenocarcinoma: Association with Angiogenesis and Poor Prognosis , 1999, Oncology.
[82] W. Wold,et al. Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. , 1999, Current opinion in immunology.
[83] G. Coukos,et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[84] R. Price,et al. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement , 1999, Gene Therapy.
[85] C. Miller,et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. , 1998, Cancer Research.
[86] C. Halbert,et al. Successful Readministration of Adeno-Associated Virus Vectors to the Mouse Lung Requires Transient Immunosuppression during the Initial Exposure , 1998, Journal of Virology.
[87] M. Coffey,et al. Reovirus therapy of tumors with activated Ras pathway. , 1998, Science.
[88] N. Dyson. The regulation of E2F by pRB-family proteins. , 1998, Genes & development.
[89] C. Caskey,et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[90] S. Ponnazhagan,et al. Recombinant Human Parvovirus B19 Vectors: Erythroid Cell-Specific Delivery and Expression of Transduced Genes , 1998, Journal of Virology.
[91] A. Beaudet,et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity , 1998, Nature Genetics.
[92] D. Curiel,et al. Endothelial cell vehicles for delivery of cytotoxic genes as a gene therapy approach for carcinoma of the ovary. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[93] J. Flint,et al. Viral transactivating proteins. , 1997, Annual review of genetics.
[94] R. Hawkins,et al. The ‘adenobody’ approach to viral targeting: specific and enhanced adenoviral gene delivery , 1997, Gene Therapy.
[95] A. Gown,et al. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[96] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[97] M. Rudnicki,et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[98] A. Fattaey,et al. An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.
[99] A. Harris,et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. , 1996, Cancer research.
[100] D. Curiel,et al. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism , 1996, Journal of virology.
[101] J. Wilson,et al. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. , 1996, Human gene therapy.
[102] P. Wen,et al. In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. , 1996, Human gene therapy.
[103] B. Trapnell,et al. Gene therapy using adenoviral vectors. , 1994, Current opinion in biotechnology.
[104] Lars Holmgren,et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.
[105] E. Furth,et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[106] C. Lewis,et al. Tumour‐associated leucocytes: Friends or foes in breast carcinoma , 1994, The Journal of pathology.
[107] S. Ben-Efraim,et al. Therapeutical effect of activated human macrophages on a human tumor line growing in nude mice , 1994, Medical oncology.
[108] S. Freeman,et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. , 1993, Cancer research.
[109] F. Graham,et al. Packaging capacity and stability of human adenovirus type 5 vectors , 1993, Journal of virology.
[110] G. Akusjärvi,et al. Proteins with transcription regulatory properties encoded by human adenoviruses. , 1993, Trends in microbiology.
[111] D M Coen,et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant , 1991, Science.
[112] P. Hearing,et al. Adenovirus early region 4 encodes two gene products with redundant effects in lytic infection , 1989, Journal of virology.
[113] E. Bridge,et al. Redundant control of adenovirus late gene expression by early region 4 , 1989, Journal of virology.
[114] F. Moolten. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. , 1986, Cancer research.
[115] Craig W. Reynolds,et al. Distribution of peritoneal macrophage populations after intravenous injection in mice: differential effects of eliciting and activating agents. , 1983, Journal of the Reticuloendothelial Society.
[116] J. Maizel,et al. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. , 1974, Virology.
[117] W. Cassel,et al. Newcastle disease virus as an antineoplastic agent , 1965, Cancer.
[118] S. Russell,et al. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[119] Jinwoo Cheon,et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging , 2007, Nature Medicine.
[120] D. Curiel,et al. Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application , 2007, Cancer Gene Therapy.
[121] A. Barberis,et al. An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery , 2006, Gene Therapy.
[122] G. Bertino,et al. Psychiatric Symptoms Induced by Antiviral Therapy in Chronic Hepatitis C , 2006, Clinical drug investigation.
[123] P. Monaci,et al. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector , 2005, International journal of cancer.
[124] G. Hashiro,et al. The preferential cytotoxicity of reovirus for certain transformed cell lines , 2005, Archives of Virology.
[125] M. Barry,et al. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[126] R. Weissleder,et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[127] E. Poeschla,et al. Lentiviral vectors. , 2005, Advances in biochemical engineering/biotechnology.
[128] R. Kontermann,et al. Retargeting of adenoviral infection to melanoma: Combining genetic ablation of native tropism with a recombinant bispecific single‐chain diabody (scDb) adapter that binds to fiber knob and HMWMAA , 2004, International journal of cancer.
[129] D. Nettelbeck,et al. Tumor-busting viruses. , 2003, Scientific American.
[130] M. Dewhirst,et al. Early wound healing exhibits cytokine surge without evidence of hypoxia. , 2000, Annals of surgery.
[131] G. Deléage,et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2 , 1999, Nature Medicine.
[132] D. Gridley,et al. Antitumor effect of vaccinia virus in glioma model. , 1999, Oncology research.
[133] C. Rüegg,et al. Clinical applications of TNF-alpha in cancer. , 1998, Current opinion in immunology.
[134] J. Chamberlain,et al. Production and Characterization of Improved Adenovirus Vectors with the E 1 , E 2 b , and E 3 Genes Deleted , 1998 .
[135] W. Wold,et al. E3 transcription unit of adenovirus. , 1995, Current topics in microbiology and immunology.
[136] G. Elion. The chemotherapeutic exploitation of virus-specified enzymes. , 1980, Advances in enzyme regulation.